… alpha-synuclein over production-a well-known causative factor in familial form PD. This proposed study is designed to … Description: We will design two versions of microRNA precursors; wild type and genetically modified. The modified microRNA will completely match that risk genetic variation in order to …

… novel classes of drugs for Parkinson's disease therapy. Our previous studies have shown that that a new class of drugs, type 7 phosphodiesterase (PDE7) inhibitors, restore normal movements in pre-clinical models of … Description: We will first test a number of PDE7 inhibitor compounds for potency, safety, ability to enter the brain, …

… with cognitive recall scores. These findings may point to symptom-specific biomarkers useful for pathological … to accelerate drug development," said MJFF Senior Vice President of Research Programs Mark Frasier, PhD, an author … of Team Fox members around the world. For more information, visit us at michaeljfox.org , on Facebook or Twitter . …

… public policy and advocacy, on September 9 – 10 in Washington, D.C. for the 2019 Parkinson’s Policy Forum. The event … for patients and their families,” said MJFF CEO Todd Sherer, PhD. “The Parkinson’s Policy Forum brings the community together to advocate for government policies that …

… Today, MJFF announced the promotion of Sohini Chowdhury to Deputy Chief Executive Officer. In her previous role as Senior Vice President of Research … helped shape the Research Partnerships team, which now encompasses MJFF's industry strategy as well as the …

… With two weeks remaining in April, there's still plenty of time to make a difference this Parkinson's Awareness Month . Team … fundraising page as a place to share your story. Let your community know why you've stepped up to help raise valuable …